Approval for changes to the labeling to incorporate the results of the 5-year postapproval study.  The device, as modified, will be marketed under the trade name tmx-2000 thermatrx office thermo therapy system and is indicated for the treatment of symptomatic benign prostatic hyperplasia (bph) in men who have a minimum prostatic urethra length of 25 mm and a total prostate volume between 30 and 100 cc.